Benzinga · Nov 11, 2026
StoneX Maintains Buy on AbCellera Biologics, Raises Price Target to $15
StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
NASDAQ · ABCL
Healthcare · Biotechnology
$11.12
Down-$0.37 (-3.22%)
Updated Nov 17, 2026, 4:48 AM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ABCL
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
ABCL closed at $11.12 after 21 trading sessions, down 6.79% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $11.23 | $11.44 | $11.03 | $11.12 | 2.47M |
| Nov 13, 2026 | $11.75 | $11.83 | $11.055 | $11.49 | 2.68M |
| Nov 12, 2026 | $11.62 | $12.005 | $11.242 | $11.62 | 3.16M |
| Nov 11, 2026 | $12.695 | $12.952 | $11.93 | $11.95 | 2.87M |
| Nov 10, 2026 | $12.265 | $12.96 | $11.9083 | $12.46 | 3.91M |
| Nov 9, 2026 | $11.90 | $12.74 | $11.682 | $12.50 | 3M |
| Nov 6, 2026 | $11.56 | $11.98 | $11.20 | $11.88 | 2.21M |
| Nov 5, 2026 | $11.88 | $11.88 | $10.76 | $11.13 | 4.15M |
| Nov 4, 2026 | $12.325 | $12.54 | $11.5305 | $12.28 | 2.67M |
| Nov 3, 2026 | $11.32 | $12.3259 | $11.28 | $12.18 | 2.5M |
| Nov 2, 2026 | $12.33 | $12.33 | $11.0525 | $11.12 | 3.04M |
| Oct 30, 2026 | $12.65 | $12.91 | $11.75 | $12.27 | 3.88M |
| Oct 29, 2026 | $13.41 | $13.86 | $13.02 | $13.08 | 2.62M |
| Oct 28, 2026 | $12.67 | $13.65 | $12.6537 | $13.64 | 3.06M |
| Oct 27, 2026 | $11.98 | $12.89 | $11.85 | $12.83 | 3.46M |
| Oct 26, 2026 | $12.02 | $12.415 | $11.78 | $12.08 | 3.04M |
| Oct 23, 2026 | $11.45 | $11.895 | $11.08 | $11.82 | 3.03M |
| Oct 22, 2026 | $11.985 | $12.23 | $11.205 | $11.37 | 4.28M |
| Oct 21, 2026 | $11.78 | $12.365 | $11.59 | $12.24 | 3.22M |
| Oct 20, 2026 | $11.65 | $11.945 | $11.41 | $11.71 | 4.26M |
| Oct 19, 2026 | $12.045 | $12.28 | $11.75 | $11.93 | 3.14M |
The latest Smart Investors Daily articles mentioning ABCL.
Company
Market Activity
Research & News
ABCL research
Company profile and research snapshot.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 11, 2026 | StoneX | Buy | — |
| Nov 10, 2026 | Stifel | Buy | — |
| Oct 12, 2026 | UBS | Buy | — |
| Sep 29, 2026 | JP Morgan | Overweight | — |
| Sep 24, 2026 | Goldman Sachs | Neutral | — |
No generated briefing is available yet.
Benzinga · Nov 11, 2026
StoneX analyst Robert Wasserman maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $11 to $15.
Yahoo · Nov 10, 2026
AbCellera Biologics Inc (ABCL) posted a narrower quarterly loss, showcased Phase 2 results for ABCL635 that rival hormone therapy, and ended the quarter with over $890 million in available liquidity.
Benzinga · Nov 10, 2026
Stifel analyst Stephen Willey maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $9 to $14.
Yahoo · Nov 10, 2026
Phase II data fueled a $200 million raise and plans for Phase III trials.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning ABCL.